Cargando…

Combination of CTLA-4 blockade with MUC1 mRNA nanovaccine induces enhanced anti-tumor CTL activity by modulating tumor microenvironment of triple negative breast cancer

The immunosuppressive tumor microenvironment (TME) is the main reason for the failure of many immunotherapies that directly stimulate anti-tumor immune response. Anti-CTLA-4 antibody may reduce effector regulatory T (Treg) cell numbers and their suppressive activity in the TME. We have previously re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Xuan, Chen, Hedan, Xie, Ying, Zhou, Xue, Wang, Yun, Zhou, Jing, Long, Shiqi, Hu, Zuquan, Zhang, Shichao, Qiu, Wei, Zeng, Zhu, Liu, Lina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8652013/ https://www.ncbi.nlm.nih.gov/pubmed/34875483 http://dx.doi.org/10.1016/j.tranon.2021.101298

Ejemplares similares

Adoptively transferred melanoma-reactive CTL primed in the presence of IL-21 and transferred with concurrent CTLA4 blockade results in enhanced CTL persistence and tumor regression
por: Yee, Cassian, et al.
Publicado: (2014)

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment
por: Poon, Edmund, et al.
Publicado: (2017)

CD80 Expression on Tumor Cells Alters Tumor Microenvironment and Efficacy of Cancer Immunotherapy by CTLA-4 Blockade
por: Vackova, Julie, et al.
Publicado: (2021)

CTLA-4 blockade during dendritic cell based booster vaccination influences dendritic cell survival and CTL expansion
por: Pedersen, Anders E, et al.
Publicado: (2007)

CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection
por: Waitz, Rebecca, et al.
Publicado: (2012)

Combined IL-21–primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient
por: Chapuis, Aude G., et al.
Publicado: (2016)

Amphiphilic polyanhydride-based recombinant MUC4β-nanovaccine activates dendritic cells
por: Banerjee, Kasturi, et al.
Publicado: (2019)

Research progress of nanovaccine in anti-tumor immunotherapy
por: Yao, Min, et al.
Publicado: (2023)

Blockade of beta-adrenergic receptors reduces cancer growth and enhances the response to anti-CTLA4 therapy by modulating the tumor microenvironment
por: Fjæstad, Klaire Yixin, et al.
Publicado: (2022)

Hybrid Membrane Nanovaccines Combined with Immune Checkpoint Blockade to Enhance Cancer Immunotherapy
por: Zhao, Peiqi, et al.
Publicado: (2022)

Prostaglandin E(2) and PD-1 mediated inhibition of antitumor CTL responses in the human tumor microenvironment
por: Miao, Jie, et al.
Publicado: (2017)

Prognostic landscape of tumor-infiltrating immune cells and immune-related genes in the tumor microenvironment of gastric cancer
por: Zhang, Shichao, et al.
Publicado: (2020)

Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models
por: Jure-Kunkel, Maria, et al.
Publicado: (2013)

CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumors
por: Zappasodi, Roberta, et al.
Publicado: (2021)

Remodeling tumor immunosuppressive microenvironment via a novel bioactive nanovaccines potentiates the efficacy of cancer immunotherapy
por: Xie, Xiaoxue, et al.
Publicado: (2022)

ICOS Costimulation at the Tumor Site in Combination with CTLA-4 Blockade Therapy Elicits Strong Tumor Immunity
por: Soldevilla, Mario Martínez, et al.
Publicado: (2019)

Identification of CTLA-4 associated with tumor microenvironment and competing interactions in triple negative breast cancer by co-expression network analysis
por: Peng, Ziqi, et al.
Publicado: (2020)

Synergistic Effect of CTLA-4 Blockade and Cancer Chemotherapy in the Induction of Anti-Tumor Immunity
por: Lesterhuis, W. Joost, et al.
Publicado: (2013)

Therapeutic efficacy of combined blockade of CTLA-4 +/- PD-L1 +/- IDO is associated with re-activation of T cells directly within the tumor microenvironment
por: Spranger, Stefani, et al.
Publicado: (2013)

MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer
por: Yamashita, Nami, et al.
Publicado: (2021)

CTLA-4 blockade boosts the expansion of tumor-reactive CD8(+) tumor-infiltrating lymphocytes in ovarian cancer
por: Friese, Christina, et al.
Publicado: (2020)

Contrasting effects of cyclophosphamide on anti‐CTL‐associated protein 4 blockade therapy in two mouse tumor models
por: Iida, Yuichi, et al.
Publicado: (2017)

CTLA4-Mediated Immunosuppression in Glioblastoma is Associated with the Infiltration of Macrophages in the Tumor Microenvironment
por: Guan, Xiudong, et al.
Publicado: (2021)

Cooperating minimalist nanovaccine with PD-1 blockade for effective and feasible cancer immunotherapy
por: Jiang, Mingxia, et al.
Publicado: (2021)

Microenvironment-Dependent Gradient of CTL Exhaustion in the AE17sOVA Murine Mesothelioma Tumor Model
por: Hope, Jennifer L., et al.
Publicado: (2020)

Correction: MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer
Publicado: (2021)

LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade
por: Hickman, Amber, et al.
Publicado: (2022)

The reactive tumor microenvironment: MUC1 signaling directly reprograms transcription of CTGF
por: Behrens, Michelle E., et al.
Publicado: (2010)

MUC1 modulates the tumor immune microenvironment through the engagement of Siglec-9
por: Beatson, Richard, et al.
Publicado: (2016)

Single-dose injectable nanovaccine-in-hydrogel for robust immunotherapy of large tumors with abscopal effect
por: Cheng, Furong, et al.
Publicado: (2023)

CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth
por: Zhou, Ru, et al.
Publicado: (2019)

CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma
por: Guo, Xiao-Jun, et al.
Publicado: (2021)

Responsive Multivesicular Polymeric Nanovaccines that Codeliver STING Agonists and Neoantigens for Combination Tumor Immunotherapy
por: Su, Ting, et al.
Publicado: (2022)

Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males
por: Saad, Mariam, et al.
Publicado: (2022)

Delivery of Immunostimulatory Cargos in Nanocarriers Enhances Anti-Tumoral Nanovaccine Efficacy
por: Schunke, Jenny, et al.
Publicado: (2023)

Combination immunotherapy with Interleukin-2 and CTLA-4 blockade decreases tumor growth and improves overall survival
por: Broucek, Joseph R, et al.
Publicado: (2013)

Unique changes in the TCR repertoire of tumor-infiltrating lymphocytes underlie the synergy of radiotherapy with CTLA-4 blockade
por: Pilones, Karsten, et al.
Publicado: (2014)

The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
por: Petitprez, Florent, et al.
Publicado: (2020)

Anti-Tumor Efficacy of an Adjuvant Built-In Nanovaccine Based on Ubiquitinated Proteins from Tumor Cells
por: Huang, Fang, et al.
Publicado: (2020)

Corrigendum: CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth
por: Zhou, Ru, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_of2pbuissk38bf4k3p0mv7643q